Expertise in
9
conditions

Dr. Stefan C. Grant

Hematology Oncology | Oncology | Hematology
Administrators Of The Tulane Educational Fund
150 S Liberty St, 
New Orleans, LA 
Accepting New Patients
Expertise in
9
conditions
Administrators Of The Tulane Educational Fund
150 S Liberty St, 
New Orleans, LA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stefan Grant is a Hematologist Oncology specialist and an Oncologist in New Orleans, Louisiana. Dr. Grant is highly rated in 9 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Grant is currently accepting new patients.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NC
Hospital Affiliations
East Jefferson General Hospital
University Medical Center New Orleans
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
150 S Liberty St, New Orleans, LA 70112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Precision Medicine for Patients With Identified Actionable Mutations at Wake Forest Baptist Comprehensive Cancer Center (WFBCCC): A Pragmatic Trial-
Precision Medicine for Patients With Identified Actionable Mutations at Wake Forest Baptist Comprehensive Cancer Center (WFBCCC): A Pragmatic Trial-
Enrollment Status: Terminated
Publish Date: July 03, 2024
Intervention Type: Drug, Diagnostic test, Other
Study Drug: Investigational Agent
Study Phase: Phase 2
Formation of a Precision Oncology Registry
Formation of a Precision Oncology Registry
Enrollment Status: Terminated
Publish Date: January 19, 2024
Intervention Type: Other
A Pilot Study Evaluating Pemetrexed in ECOG Performance Status 3 Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
A Pilot Study Evaluating Pemetrexed in ECOG Performance Status 3 Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Other, Drug
Study Drug: Pemetrexed Disodium
Study Phase: Phase 2
A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients
A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients
Enrollment Status: Completed
Publish Date: August 07, 2023
Intervention Type: Drug, Other
Study Drugs: 6,8-Bis(benzylthio)octanoic acid, Fluorouracil
Study Phase: Phase 1
A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status
A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status
Enrollment Status: Completed
Publish Date: July 12, 2023
Intervention Type: Drug, Other
Study Drugs: 6,8-Bis(Benzylthio)Octanoic Acid, Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil
Study Phase: Phase 1
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Enrollment Status: Unknown
Publish Date: June 12, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Etoposide, Carboplatin
Study Phase: Phase 3
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
Enrollment Status: Completed
Publish Date: May 15, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status
A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status
Enrollment Status: Completed
Publish Date: December 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Open-Label Dose Escalation Trial of CPI-613 in Combination With Docetaxel Chemotherapy as a Second-Line Treatment of Non-Small-Cell Lung Cancer
A Phase I/II Open-Label Dose Escalation Trial of CPI-613 in Combination With Docetaxel Chemotherapy as a Second-Line Treatment of Non-Small-Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: August 01, 2018
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

24 Total Publications

Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations.
Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations.
Journal: JNCI cancer spectrum
Published: December 06, 2022
Similar Doctors
Expertise in
39
conditions
Dr. Marc R. Matrana
Hematology Oncology | Hospital Medicine | Hematology
Expertise in
39
conditions
Dr. Marc R. Matrana
Hematology Oncology | Hospital Medicine | Hematology

Ochsner Clinic LLC

1514 Jefferson Hwy, 
New Orleans, LA 
 (4.3 miles away)
504-842-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marc Matrana is a Hematologist Oncology specialist and a Hospital Medicine provider in New Orleans, Louisiana. Dr. Matrana is highly rated in 39 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Lung Cancer, Urothelial Cancer, Adult Soft Tissue Sarcoma, and Nephrectomy. Dr. Matrana is currently accepting new patients.

Expertise in
10
conditions
Dr. John T. Cole
Hematology Oncology | Hematology | Oncology
Expertise in
10
conditions
Dr. John T. Cole
Hematology Oncology | Hematology | Oncology

Ochsner Clinic LLC

1514 Jefferson Hwy, 
New Orleans, LA 
 (4.3 miles away)
504-842-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Cole is a Hematologist Oncology specialist and a Hematologist in New Orleans, Louisiana. Dr. Cole is highly rated in 10 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Cole is currently accepting new patients.

Expertise in
5
conditions
Dr. Bridgette M. Collins-Burow
Hematology Oncology | Hematology | Oncology
Expertise in
5
conditions
Dr. Bridgette M. Collins-Burow
Hematology Oncology | Hematology | Oncology

Administrators Of The Tulane Educational Fund

1415 Tulane Ave, 
New Orleans, LA 
 (0.1 miles away)
504-988-5800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bridgette Collins-Burow is a Hematologist Oncology specialist and a Hematologist in New Orleans, Louisiana. Dr. Collins-Burow is highly rated in 5 conditions, according to our data. Her top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer. Dr. Collins-Burow is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grant's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile